Citi Pharma (KAR:CPHL) EV-to-EBITDA: (As of Sep. 13, 2026)

Citi Pharma  (KAR:CPHL) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Citi Pharma's PE Ratio (TTM) for today is calculated as:

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

Citi Pharma EV-to-EBITDA Related Terms

The historical data trend for Citi Pharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citi Pharma EV-to-EBITDA Chart

KAR:CPHL vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Citi Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Citi Pharma EV-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citi Pharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Citi Pharma's EV-to-EBITDA falls into.

Citi Pharma EV-to-EBITDA Calculation

Citi Pharma's EV-to-EBITDA for today is calculated as:

Citi Pharma Business Description